샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514171

세계의 기면증 치료제 시장

Narcolepsy Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 363 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

기면증 치료제 시장은 2030년까지 36억 달러에 달할 전망입니다.

2023년에 22억 달러로 평가된 기면증 치료제 시장은 2030년에는 36억 달러에 이를 전망이며, 예측 기간 동안 복합 연간 성장률(CAGR) 7.2%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 카타플렉시를 동반한 기면증 치료제는 복합 연간 성장률(CAGR) 6.9%로 성장을 지속하고, 분석 기간 종료까지 19억 달러에 달할 것으로 예측됩니다. 카타플렉시가 없는 난콜렙시 치료제 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 8.1%로 추정됩니다.

미국 시장은 5억 9,690만 달러로 예측됩니다. 중국은 복합 연간 성장률(CAGR) 11.5%로 성장할 것으로 예측됩니다.

2023년 5억 9,690만 달러로 미국의 날콜레시 치료제 시장이 추정됩니다. 세계 2위 경제대국인 중국은 예측 기간 동안 복합 연간 성장률(CAGR) 11.5%를 견인해 2030년까지 8억 3,380만 달러 규모에 이를 것으로 예측되고 있습니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 2.8%와 7.4%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 4.1%로 성장할 것으로 예측됩니다.

기면증 치료제 - 주요 동향 및 촉진요인

기면증은 낮 동안 과도한 졸음, 담뱃대, 수면 마비, 환각 등을 특징으로하는 만성 신경 질환으로,이 질병으로 고통받는 사람들의 요구에 대응하는 의학 연구 및 치료의 중요한 분야입니다. 나르콜렙시 치료의 첫 번째 목표는 증상을 관리하고 환자의 삶의 질을 향상시키는 것입니다. 현재의 치료 옵션은 자극제, 옥시베이트 나트륨, 선택적 세로토닌-노르에피네프린 재흡수 억제제(SNRI)와 같은 약물을 포함합니다. 모다피닐과 알모다피닐과 같은 각성제는 각성을 촉진함으로써 낮 동안 과도한 졸음을 다루는데 도움이 되며, 옥시베이트 나트륨은 카타플렉시를 줄이고 야간 수면을 개선하는 데 효과적입니다. 또한 SNRI 및 기타 항우울제도 카타플렉시 및 기타 관련 증상을 관리하는 데 사용됩니다. 이러한 약물은 종종 병용되며, 항문증의 다양한 증상을 반영하는 맞춤형 치료 접근법을 제공합니다.

기면증 치료제의 최근 진보는 환자의 예후를 현저하게 개선하고 치료 전망을 넓혀 왔습니다. 새로운 오렉신 수용체 작용제와 같은 혁신적인 약물은 치료 개발의 최전선에 있습니다. 오렉신은 각성을 조절하는 신경 펩티드이며, 많은 날콜레시 환자, 특히 1형 날콜레시 환자에서는 결핍되어 있습니다. 오렉신 수용체 작용제는 오렉신의 작용을 모방하여 과도한 졸음과 카타플렉시의 근본 원인에 대처하는 것을 목적으로 하고 있습니다. 게다가, 유전자 조사와 바이오마커 식별 진보는 보다 정확하고 맞춤 치료 전략에 대한 길을 열고 있습니다. 이러한 개발은 기존 치료법의 효능을 높일 뿐만 아니라 새로운 치료 대상의 발견에도 기여하고 있습니다. 모바일 앱 및 웨어러블 디바이스와 같은 디지털 헬스 기술의 통합은 또한 난콜랩시 관리에 중요한 역할을 합니다. 이러한 기술은 수면 패턴과 복약 준수를 지속적으로 모니터링하고 치료 계획을 최적화하는 데 사용할 수 있는 귀중한 데이터를 제공합니다.

기면증 치료제 시장의 성장은 여러 요인에 의해 야기됩니다. 기면증에 대한 인식과 진단이 증가함에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다. 의학 연구, 특히 기면증의 유전적,분자적 기반의 해명에 있어서의 연구개발이 혁신적인 치료법의 개발을 뒷받침하고 있습니다. 기면증의 유병률의 상승은 헬스케어 인프라의 개선과 함께 진단,치료 서비스에 대한 액세스를 향상시키고 있습니다. 게다가, 맞춤형 의료가 받아들여지고 있는 것이, 유전자나 바이오마커 정보에 근거해 개개의 환자프로파일에 맞춘 표적 요법의 채용을 뒷받침하고 있습니다. 제약회사는 보다 효과적인 신규 기면증 치료제를 상시하기 위해 연구개발에 많은 투자를 하고 있습니다. 또한 신규 기면증 치료제에 대한 규제 당국의 지원이나 희소질환용 의약품의 지정도 신규 치료제의 개발을 뒷받침하고 있습니다. 또한 환자 지원 단체는 인지도 향상, 연구 자금 제공, 임상시험 지원에 중요한 역할을 하며 시장 성장에 기여하고 있습니다. 이러한 요인들이 합쳐져, 기면증 치료제 시장의 역동적이고 진화적인 성질이 강조되어 향후 수년간 환자에게 더 나은 결과를 가져올 것으로 기대됩니다.

조사 대상 기업 예(전 14건)

  • Arena Pharmaceuticals, Inc.
  • BioProjet Pharma
  • Graymark Healthcare, Inc.
  • Jazz Pharmaceuticals PLC
  • Ligand Pharmaceuticals, Inc.
  • Shionogi, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global Narcolepsy Therapeutics Market to Reach US$3.6 Billion by 2030

The global market for Narcolepsy Therapeutics estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. Narcolepsy with Cataplexy Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Narcolepsy without Cataplexy Therapeutics segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$596.9 Million While China is Forecast to Grow at 11.5% CAGR

The Narcolepsy Therapeutics market in the U.S. is estimated at US$596.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$833.8 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Narcolepsy Therapeutics - Key Trends and Drivers

Narcolepsy therapeutics represent a critical area of medical research and treatment, addressing the needs of individuals afflicted by this chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations. The primary goal of narcolepsy treatment is to manage symptoms and improve patients' quality of life. Current therapeutic options include medications such as stimulants, sodium oxybate, and selective serotonin and norepinephrine reuptake inhibitors (SNRIs). Stimulants like modafinil and armodafinil help combat excessive daytime sleepiness by promoting wakefulness, while sodium oxybate is effective in reducing cataplexy and improving nighttime sleep. Additionally, SNRIs and other antidepressants are utilized to manage cataplexy and other associated symptoms. These medications, often used in combination, provide a tailored approach to treatment, reflecting the diverse manifestations of narcolepsy.

Recent advancements in narcolepsy therapeutics are significantly enhancing patient outcomes and expanding the treatment landscape. Innovations such as novel orexin receptor agonists are at the forefront of therapeutic development. Orexin, a neuropeptide that regulates wakefulness, is deficient in many individuals with narcolepsy, particularly those with type 1 narcolepsy. Orexin receptor agonists aim to mimic the action of orexin, thereby addressing the root cause of excessive sleepiness and cataplexy. Furthermore, advancements in genetic research and biomarker identification are paving the way for more precise and personalized treatment strategies. These developments not only enhance the efficacy of existing treatments but also contribute to the discovery of new therapeutic targets. The integration of digital health technologies, including mobile apps and wearable devices, is also playing a crucial role in managing narcolepsy. These technologies enable continuous monitoring of sleep patterns and medication adherence, providing valuable data that can be used to optimize treatment plans.

The growth in the narcolepsy therapeutics market is driven by several factors. Increasing awareness and diagnosis of narcolepsy are leading to a higher demand for effective treatments. Advancements in medical research, particularly in understanding the genetic and molecular basis of the disorder, are driving the development of innovative therapies. The rising prevalence of narcolepsy, coupled with improved healthcare infrastructure, is facilitating better access to diagnostic and therapeutic services. Additionally, the growing acceptance of personalized medicine is propelling the adoption of targeted therapies, which are tailored to individual patient profiles based on genetic and biomarker information. Pharmaceutical companies are investing heavily in research and development to bring new and more effective narcolepsy treatments to market. Regulatory support and the designation of orphan drug status for new narcolepsy medications are also incentivizing the development of novel therapeutics. Furthermore, patient advocacy groups are playing a crucial role in raising awareness, funding research, and supporting clinical trials, thereby contributing to market growth. These factors collectively underscore the dynamic and evolving nature of the narcolepsy therapeutics market, promising better outcomes for patients in the years to come.

Select Competitors (Total 14 Featured) -

  • Arena Pharmaceuticals, Inc.
  • BioProjet Pharma
  • Graymark Healthcare, Inc.
  • Jazz Pharmaceuticals PLC
  • Ligand Pharmaceuticals, Inc.
  • Shionogi, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Narcolepsy Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnosis of Narcolepsy Spurs Demand for Therapeutics
    • Advances in Genetic Research Throw the Spotlight on Personalized Narcolepsy Treatments
    • Innovations in Orexin Receptor Agonists Propel Growth in Narcolepsy Therapeutics Market
    • Integration of Digital Health Technologies Expands Addressable Market Opportunity
    • Improved Healthcare Infrastructure Strengthens Business Case for Narcolepsy Treatments
    • Pharmaceutical Investments in R&D Accelerate Development of Advanced Narcolepsy Drugs
    • Patient Advocacy Groups Drive Market Growth and Research Funding
    • Increasing Prevalence of Narcolepsy Generates Demand for Effective Treatment Options
    • Rising Acceptance of Personalized Medicine Throws the Spotlight on Targeted Therapies
    • Enhanced Understanding of Molecular Mechanisms Improves Treatment Efficacy
    • Early Diagnosis Techniques Strengthen Business Case for Comprehensive Treatment Plans
    • Expansion of Clinical Trials Accelerates New Therapeutic Approvals
    • Advances in Drug Delivery Systems Propel Growth in Narcolepsy Therapeutics Market
    • Global Initiatives and Funding for Sleep Disorders Research Drives Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Narcolepsy Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Narcolepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Narcolepsy with Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Narcolepsy with Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Narcolepsy with Cataplexy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Narcolepsy without Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Narcolepsy without Cataplexy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Narcolepsy without Cataplexy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Secondary Narcolepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Secondary Narcolepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Secondary Narcolepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sodium Oxybate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sodium Oxybate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Sodium Oxybate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Central Nervous System Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Central Nervous System Stimulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Selective Serotonin Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Selective Serotonin Reuptake Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Tricyclic Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • JAPAN
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • CHINA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • EUROPE
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Narcolepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • FRANCE
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • GERMANY
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • INDIA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Narcolepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Narcolepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030
  • AFRICA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Narcolepsy Therapeutics by Type - Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Narcolepsy Therapeutics by Type - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Narcolepsy Therapeutics by Product - Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Narcolepsy Therapeutics by Product - Percentage Breakdown of Value Sales for Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants and Other Products for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제